{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:52:40Z","timestamp":1788850360672,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.tmrv.2022.07.001","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T02:52:46Z","timestamp":1662519166000},"page":"215-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Advances in Acquired Hemophilia A"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2431-5106","authenticated-orcid":false,"given":"Jacqueline N","family":"Poston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Kruse-Jarres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.tmrv.2022.07.001_bib0001","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1471-0528.2012.03469.x","article-title":"Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry","volume":"119","author":"Tengborn","year":"2012","journal-title":"BJOG"},{"issue":"4","key":"10.1016\/j.tmrv.2022.07.001_bib0002","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1538-7836.2012.04654.x","article-title":"Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"10","author":"Knoebl","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"Suppl 3","key":"10.1016\/j.tmrv.2022.07.001_bib0003","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2516.2010.02259.x","article-title":"Genetic markers in acquired haemophilia","volume":"16","author":"Oldenburg","year":"2010","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.tmrv.2022.07.001_bib0004","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00277-009-0887-3","article-title":"Acquired haemophilia caused by non-haemophilic factor VIII gene variants","volume":"89","author":"Tiede","year":"2010","journal-title":"Ann Hematol"},{"issue":"102","key":"10.1016\/j.tmrv.2022.07.001_bib0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2516.2008.01976.x","article-title":"HLA genotype in patients with acquired haemophilia A","volume":"16","author":"Pavlova","year":"2010","journal-title":"Haemophilia"},{"issue":"7","key":"10.1016\/j.tmrv.2022.07.001_bib0006","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.tmrv.2022.07.001_bib0007","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/hae.12138","article-title":"Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l'H\u00e9mophilie Acquise) registry","volume":"19","author":"Borg","year":"2013","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.tmrv.2022.07.001_bib0008","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1055\/s-0037-1615080","volume":"79","author":"Giles","year":"1998","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.tmrv.2022.07.001_bib0009","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/j.1538-7836.2010.04090.x","article-title":"Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required","volume":"8","author":"Favaloro","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.tmrv.2022.07.001_bib0010","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ajh.21666","article-title":"Avoiding errors in the laboratory evaluation of potent lupus anticoagulants","volume":"85","author":"Penmetsa","year":"2010","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.tmrv.2022.07.001_bib0011","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12185-021-03212-9","article-title":"Measurement of coagulation factor antibody levels is useful for diagnosis and determining therapeutic efficacy in hemorrhagic patients with autoantibodies to coagulation factor VIII and factor V: results from a single center in Japan","volume":"115","author":"Ieko","year":"2022","journal-title":"Int J Hematol"},{"issue":"7","key":"10.1016\/j.tmrv.2022.07.001_bib0012","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1182\/blood-2014-09-598268","article-title":"Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans","volume":"125","author":"Hofbauer","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.tmrv.2022.07.001_bib0013","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1160\/TH14-12-1062","article-title":"Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A","volume":"114","author":"Batty","year":"2015","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.tmrv.2022.07.001_bib0014","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/jth.13304","article-title":"Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01\/2010 study","volume":"14","author":"Werwitzke","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1016\/j.tmrv.2022.07.001_bib0015","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood-2014-07-587089","article-title":"Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01\/2010 study","volume":"125","author":"Tiede","year":"2015","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.tmrv.2022.07.001_bib0016","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood-2015-09-672774","article-title":"Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01\/2010 study","volume":"127","author":"Tiede","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.tmrv.2022.07.001_bib0017","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1111\/jth.15515","article-title":"Predictive significance of anti-FVIII immunoglobulin patterns on bleeding phenotype and outcomes in acquired hemophilia A: results from the Quebec Reference Center for Inhibitors","volume":"19","author":"Bonnefoy","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.tmrv.2022.07.001_bib0018","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2012-02-409185","article-title":"Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"120","author":"Collins","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.tmrv.2022.07.001_bib0019","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bjh.12829","article-title":"Inhibitor eradication with rituximab in haemophilia: where do we stand?","volume":"165","author":"Franchini","year":"2014","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.tmrv.2022.07.001_bib0020","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1007\/s00277-020-04150-y","article-title":"Reduced-intensity, risk factor-stratified immunosuppression for acquired hemophilia A: single-center observational study","volume":"99","author":"Dobbelstein","year":"2020","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.tmrv.2022.07.001_bib0021","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2012-02-408930","article-title":"Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry","volume":"120","author":"Baudo","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.tmrv.2022.07.001_bib0022","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/hae.12627","article-title":"Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A","volume":"21","author":"Kruse-Jarres","year":"2015","journal-title":"Haemophilia"},{"issue":"16","key":"10.1016\/j.tmrv.2022.07.001_bib0023","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.tmrv.2022.07.001_bib0024","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/hae.14450","article-title":"Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: a scoping review of the literature","volume":"28","author":"Thomas","year":"2022","journal-title":"Haemophilia"},{"issue":"Suppl. 1","key":"10.1016\/j.tmrv.2022.07.001_bib0025","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2021-148040","article-title":"Emicizumab for the treatment of acquired Hemophilia a: a multicenter US case series","volume":"138","author":"Poston","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.tmrv.2022.07.001_bib0026","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1055\/s-0039-1688687","article-title":"Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays","volume":"119","author":"Adamkewicz","year":"2019","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.tmrv.2022.07.001_bib0027","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s12185-020-02823-y","article-title":"Overshoot of FVIII activity in patients with acquired hemophilia A who achieve complete remission","volume":"111","author":"Ogawa","year":"2020","journal-title":"Int J Hematol"},{"issue":"11","key":"10.1016\/j.tmrv.2022.07.001_bib0028","article-title":"Anticoagulation for stroke prevention after restoration of haemostasis with emicizumab in acquired Haemophilia A","volume":"8","author":"Al-Banaa","year":"2021","journal-title":"Eur J Case Rep Intern Med"},{"issue":"8","key":"10.1016\/j.tmrv.2022.07.001_bib0029","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1111\/jth.14887","article-title":"Non-additive effect on thrombin generation when a plasma-derived factor VIII\/von Willebrand factor (FVIII\/VWF) is combined with emicizumab in vitro","volume":"18","author":"Bravo","year":"2020","journal-title":"J Thromb Haemost"}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796322000384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796322000384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:20:42Z","timestamp":1760138442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796322000384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0887796322000384"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2022.07.001","relation":{},"ISSN":["0887-7963"],"issn-type":[{"value":"0887-7963","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Acquired Hemophilia A","name":"articletitle","label":"Article Title"},{"value":"Transfusion Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmrv.2022.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}